LifeMD (LFMD) EBITDA (2012 - 2025)

LifeMD (LFMD) has reported EBITDA for 14 consecutive years, with -$6.2 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 4.26% year-over-year to -$6.2 million; the trailing twelve-month figure through Dec 2025 stood at -$7.7 million (up 65.82% YoY), and the FY2025 full-year result was -$7.7 million, up 62.41% from the prior year.
• EBITDA eased to -$6.2 million in Q4 2025 per LFMD's latest filing, from -$2.0 million in the prior quarter.
• Across five years, EBITDA topped out at $974342.0 in Q1 2025 and bottomed at -$16.1 million in Q2 2021.
• Historically, EBITDA has averaged -$7.1 million across 5 years, with a median of -$6.2 million in 2024.
• The sharpest annual moves came in 2021 and 2025: EBITDA plunged 584.76% in 2021, then surged 115.79% in 2025.
• Over 5 years, EBITDA stood at -$13.7 million in 2021, then rose by 24.1% to -$10.4 million in 2022, then surged by 79.06% to -$2.2 million in 2023, then sank by 174.87% to -$6.0 million in 2024, then retreated by 4.26% to -$6.2 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$6.2 million, -$2.0 million, and -$451562.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.